Investor Presentation regarding Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30, 2026.

Q1FY27 results (unaudited): Standalone: Revenue 3.3bn +4% y-y (3.2bn) EBITDA 1.2bn +17% y-y (1.0bn) EBITDA margin 34% (31%) +300 bps y-y PAT 0.3bn +8% y-y (0.3bn) Consolidated: Revenue 6.7bn +36% y-y (4.9bn) EBITDA 1.7bn +35% y-y (1.3bn) EBITDA margin 26% (26%) 0 bps y-y PAT 0.5bn +6% y-y (0.5bn) FY26 results: Standalone: Revenue 16.8bn EBITDA 4.3bn EBITDA margin 25% PAT 1.6bn Consolidated: Revenue 23.8bn EBITDA 5.4bn EBITDA margin 23% PAT 2.2bn Commentary: Company achieved world's first commercialization of ETFA using flow chemistry and signed a $300 million LOI with BASQUEVOLT, S.A. Acquisition of Bliss GVS Pharma and Jayhawk Fine Chemicals progressing to strengthen pharmaceutical and specialty chemicals platforms.